280.83
+5.09(+1.85%)
Currency In USD
| Previous Close | 275.74 |
| Open | 276 |
| Day High | 281.56 |
| Day Low | 270 |
| 52-Week High | 317.72 |
| 52-Week Low | 26.7 |
| Volume | 519,411 |
| Average Volume | 1.12M |
| Market Cap | 5.94B |
| PE | -21.64 |
| EPS | -12.98 |
| Moving Average 50 Days | 229.61 |
| Moving Average 200 Days | 97.43 |
| Change | 5.09 |
If you invested $1000 in Praxis Precision Medicines, Inc. (PRAX) since IPO date, it would be worth $673.45 as of January 14, 2026 at a share price of $280.83. Whereas If you bought $1000 worth of Praxis Precision Medicines, Inc. (PRAX) shares 5 years ago, it would be worth $312.97 as of January 14, 2026 at a share price of $280.83.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
GlobeNewswire Inc.
9 hours ago
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy Designation from the FDA Multiple registrational readouts expected across vormatrigine, relutrig
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
GlobeNewswire Inc.
Jan 08, 2026 9:45 PM GMT
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characte